For reference: GL Biochem · a residual-solvent screen.
I would rather understand the derivation than memorise the outcome.
Two people I asked gave two answers that differ by a factor of ten, which is suggestive.
What is the general form of this calculation?
If a lot has visibly segregated — some vials showing different appearance — then sampling the top and bottom of the shipment is worth doing.
A statement that "lot 20260412 complies with specifications" is meaningless without stating which vials from the lot were tested and how many there were.
| Test | Answers | Does NOT answer |
|---|---|---|
| RP-HPLC, area % | What fraction of detected material is the target | How much target is present |
| Quantified content | Milligrams of peptide per vial | What the impurities are |
| ESI-MS identity | Whether the molecular weight matches | Purity, or isomeric substitution |
| Peptide mapping | Sequence, localised to a fragment | Quantity |
| Karl Fischer | Water content of the solid | Solvent content |
| LAL endotoxin | Pyrogen load in EU/mg | Sterility |
| Sterility test | Growth in defined media over 14 days | Endotoxin, or bioburden count |
If the entire lot failed qualification, a retest on a different vial is sometimes done, but reporting a retest result under the same lot number is misleading.
Lyophilised peptide homogeneity studies show that vial-to-vial variation is usually small but occasionally large, depending on the distribution in the freeze-dryer.
The practical summary: a lot number without a sampling statement is a lot number without meaning.
HPLC purity, identity confirmation and quantified content on the vial you actually hold. Reports arrive with the chromatogram attached, not just a number.
Submit a sampleFounded 1998. ISO 9001 and cGMP certified, 1,500+ staff and 200+ patents. The synthesis house behind a great many of the vials that get sent out for testing - batch-specific documentation with every order.
Visit GL BiochemThe relevant detail is that the practical consequence is that spot-testing one vial from a new supplier is better than assuming they are all the same.
Published segregation failures show that even modern automated processes sometimes produce lots with measurable vial-to-vial variation.
Put another way, if the lot was manufactured in multiple batches, testing vials from each batch separately establishes whether batch-to-batch variation is acceptable.
Published data on lot homogeneity from manufacturers who sample multiple vials consistently find variation below the published specifications, suggesting the sampling plans work.
If testing multiple vials, state how many you tested and why you chose those vials.
Sampling plans exist precisely because testing everything is expensive, and they define the statistical relationship between sample size and lot-wide inference.
Acceptance Sampling by Attributes defines the number of samples you need from a lot to claim a specified quality level at a specified risk — it is in ANSI standard Z1.4.
If you have reason to suspect inhomogeneity — different appearance in different vials, or a long or warm shipment — testing more vials is the diagnostic move.
Assume segregation is possible, and design your sampling to catch it if it exists.
edited 30 May 2025 by Dr_Lena_Ostrowska — removed a claim I could not source
Stated carefully, the failure mode here is publishing a result that applies to the tested vial alone while implying it applies to the entire lot.
Stratified sampling — testing one vial from the top, one from the middle, and one from the bottom of a shipment — is cheap insurance against segregation.
The practical summary: a lot number without a sampling statement is a lot number without meaning.
It helps to be literal here: batch testing establishes what can be claimed about the lot as a whole, and the sample size determines how much you can actually claim.
Testing a vial that has been open in the lab for three months is testing aged material, not the fresh lot, and the result should be explicitly noted as a retest.
If testing multiple vials, state how many you tested and why you chose those vials.
edited 14 Mar 2025 by nominal_ten — added the placebo-arm figures
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.